Pinhole imaging of131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma
β Scribed by Roberto Accorsi; MichaelJ. Morowitz; Martin Charron; JohnM. Maris
- Publisher
- Springer-Verlag
- Year
- 2003
- Tongue
- English
- Weight
- 656 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0301-0449
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Poor results with 131I-meta-iodobenzylguanidine (MIBG) therapy have been obtained in two children with stage IV neuroblastoma treated after partial surgery and unsatisfactory combination chemotherapy. Both patients' response to treatment (four and three 1-month-spaced courses, respectively; cumulati
Effects of high activities of I 131 meta-iodobenzylguanidine (mIBG) were evaluated in nine children with advanced neuroblastoma. All patients had been previously heavily treated and had either primarily refractory disease or resistant relapse. Twenty-two doses of mIBG labeled with 1.3 to 4 GBq (35-1
Background. Standard chemo-radiotherapy methods for the treatment of children with advanced neuroblastoma (NBL) including bone marrow transplant approaches have been disappointing. These poor results can be ascribed to the evolution of residual drug-resistant cell populations. Curative attempts shou
Eight patients affected by neuroblastoma were treated with 18 courses of 131I-meta-iodobenzylguanidine (MIBG). They all had been judged as "nonresponders" to conventional treatments. Six had stage IV disease: of these, five, with massive marrow involvement, had poor results, mainly because of marrow